GlassScriptPhysician profile
Stephen H Blaydes
NPI 1437181054
$6,442.13
in general payments reported to CMS, 2019-2025
16 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $170 · 2021: $81.21 · 2022: $152 · 2023: $5,493 · 2024: $266 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $5,378 · Food and Beverage: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $5,378.06 |
| Food and Beverage | $558.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $5,618.97 | 2019-2023 | Clareon, Argos |
| Johnson & Johnson Surgical Vision, INC. | $165.53 | 2023-2024 | Tecnis Iol, Veritas Vision System |
| Abbvie INC. | $86.59 | 2023-2025 | Lumigan, Alphagan P |
| Allergan, INC. | $81.80 | 2019-2021 | |
| Amgen INC. | $78.57 | 2024-2025 | Tepezza |
| Astellas Pharma US INC | $78.46 | 2024-2025 | Izervay |
| Mallinckrodt Hospital Products INC. | $71.56 | 2021-2025 | Acthar |
| Aerie Pharmaceuticals, INC. | $66.96 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $43.74 | 2022-2023 | Amvisc Plus |
| Dompe US, INC. | $36.93 | 2025 | Oxervate |
| Omeros Corporation | $28.36 | 2019 | |
| Rxsight INC | $27.12 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.69 | 2020 | |
| Horizon Therapeutics Plc | $15.06 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $14.56 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lombart Brothers, INC. | $10.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Blaydes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.